Physician-reported barriers and facilitators to thyroid hormone deprescribing in older adults.

Brandon Moretti, Rachel Livecchi, Stephanie R Taylor, Susan C Pitt, Brittany L Gay, Megan R Haymart, Arti Bhan, Jennifer Perkins, Maria Papaleontiou
{"title":"Physician-reported barriers and facilitators to thyroid hormone deprescribing in older adults.","authors":"Brandon Moretti, Rachel Livecchi, Stephanie R Taylor, Susan C Pitt, Brittany L Gay, Megan R Haymart, Arti Bhan, Jennifer Perkins, Maria Papaleontiou","doi":"10.1111/jgs.19219","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Thyroid hormone is one of the most commonly prescribed medications in the United States. Misuse of and overtreatment with thyroid hormone is common in older adults and can lead to cardiovascular and skeletal adverse events. Even though deprescribing can reduce inappropriate care, no studies have yet explored specific barriers and facilitators to guide thyroid hormone deprescribing in older adults (defined as discontinuation of thyroid hormone when initiated without an appropriate indication or dose reduction in those overtreated).</p><p><strong>Methods: </strong>We conducted semi-structured interviews with 19 endocrinologists, geriatricians, and primary care physicians who prescribe thyroid hormone. Interviews were completed between July 2020 and December 2021 via two-way video conferencing. We used both an inductive and deductive content analysis guided by the Theoretical Domains Framework to evaluate transcribed and coded participant responses. Thematic analysis characterized themes related to barriers and facilitators to thyroid hormone deprescribing practices in older adults.</p><p><strong>Results: </strong>The most commonly reported barriers to thyroid hormone deprescribing were related to patient-level factors, followed by physician- and system-level factors. Patient factors included patients' perceived need for thyroid hormone use and patient anxiety/concerns about potential side effects related to thyroid hormone dose reduction, patient lack of knowledge, and misinformation regarding deprescribing. Physician- and system-level barriers included clinic visit time constraints, physician inertia, physician lack of knowledge about deprescribing, perceived lack of sufficient patient follow-up, and electronic health record limitations. The most prominent physician-reported facilitators to thyroid hormone deprescribing were effective physician-to-patient communication, and positive physician-patient relationship, including patients' trust in their treating physician.</p><p><strong>Conclusion: </strong>Barriers and facilitators to thyroid hormone deprescribing in older adults were reported at multiple levels including patient-, physician-, and system-level factors. Interventions to improve thyroid hormone deprescribing in older adults should aim to improve patient education and expectations, increase multidisciplinary physician awareness, and overcome physician inertia.</p>","PeriodicalId":94112,"journal":{"name":"Journal of the American Geriatrics Society","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Geriatrics Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/jgs.19219","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Thyroid hormone is one of the most commonly prescribed medications in the United States. Misuse of and overtreatment with thyroid hormone is common in older adults and can lead to cardiovascular and skeletal adverse events. Even though deprescribing can reduce inappropriate care, no studies have yet explored specific barriers and facilitators to guide thyroid hormone deprescribing in older adults (defined as discontinuation of thyroid hormone when initiated without an appropriate indication or dose reduction in those overtreated).

Methods: We conducted semi-structured interviews with 19 endocrinologists, geriatricians, and primary care physicians who prescribe thyroid hormone. Interviews were completed between July 2020 and December 2021 via two-way video conferencing. We used both an inductive and deductive content analysis guided by the Theoretical Domains Framework to evaluate transcribed and coded participant responses. Thematic analysis characterized themes related to barriers and facilitators to thyroid hormone deprescribing practices in older adults.

Results: The most commonly reported barriers to thyroid hormone deprescribing were related to patient-level factors, followed by physician- and system-level factors. Patient factors included patients' perceived need for thyroid hormone use and patient anxiety/concerns about potential side effects related to thyroid hormone dose reduction, patient lack of knowledge, and misinformation regarding deprescribing. Physician- and system-level barriers included clinic visit time constraints, physician inertia, physician lack of knowledge about deprescribing, perceived lack of sufficient patient follow-up, and electronic health record limitations. The most prominent physician-reported facilitators to thyroid hormone deprescribing were effective physician-to-patient communication, and positive physician-patient relationship, including patients' trust in their treating physician.

Conclusion: Barriers and facilitators to thyroid hormone deprescribing in older adults were reported at multiple levels including patient-, physician-, and system-level factors. Interventions to improve thyroid hormone deprescribing in older adults should aim to improve patient education and expectations, increase multidisciplinary physician awareness, and overcome physician inertia.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
医生报告的老年人停用甲状腺激素的障碍和促进因素。
背景:甲状腺激素是美国最常用的处方药之一:甲状腺激素是美国最常用的处方药之一。甲状腺激素的滥用和过度治疗在老年人中很常见,可导致心血管和骨骼不良事件。尽管停用甲状腺激素可以减少不适当的治疗,但目前还没有研究探讨指导老年人停用甲状腺激素的具体障碍和促进因素(指在没有适当适应症的情况下停用甲状腺激素,或在过度治疗的情况下减少剂量):我们对 19 名开具甲状腺激素处方的内分泌科医生、老年病科医生和初级保健医生进行了半结构化访谈。访谈于 2020 年 7 月至 2021 年 12 月期间通过双向视频会议完成。在理论领域框架的指导下,我们采用了归纳和演绎内容分析的方法来评估转录和编码的参与者回答。主题分析描述了与老年人甲状腺激素处方障碍和促进因素相关的主题:最常报告的甲状腺激素处方障碍与患者层面的因素有关,其次是医生和系统层面的因素。患者因素包括患者对使用甲状腺激素的需求感知、患者对甲状腺激素剂量减少可能产生的副作用的焦虑/担忧、患者缺乏相关知识以及有关停药的错误信息。医生和系统层面的障碍包括门诊时间限制、医生惰性、医生对减量用药缺乏了解、认为缺乏足够的患者随访以及电子健康记录的限制。在医生的报告中,甲状腺激素处方最主要的促进因素是医生与患者之间的有效沟通以及积极的医患关系,包括患者对主治医生的信任:老年人停用甲状腺激素的障碍和促进因素涉及多个层面,包括患者、医生和系统层面的因素。改善老年人甲状腺激素处方的干预措施应着眼于改善对患者的教育和期望,提高多学科医生的认识,并克服医生的惰性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊介绍:
期刊最新文献
The art of aging gracefully. Factors associated with language concordant cognitive testing among linguistically diverse older adults. Denosumab for osteoporosis in older adults in long-term care: A randomized trial. Change in frailty among older COVID-19 survivors. Stress tests and biomarkers of resilience: Proceedings of the second state of resilience science conference.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1